Tag Archives: Emerging Markets

Emerging Countries' R&D: A Contest, but No Wipe Out

By Clark Herman | Published: March 5, 2013
Emerging country markets are widely viewed as Big Pharma’s ace in the hole to replace declining rates of innovation in the US and Europe, with numerous studies claiming the BRICK nations (the ‘K’ is from South Korea) are at the center of a revolutionary global shift in the source points for new ideas —  what [...]
Posted in Emerging Markets, Global, IP, R&D | Also tagged , , | 2 Comments

Can Emerging Markets Emerge Fast Enough?

By Ben Comer | Published: July 12, 2012
The IMS Institute’s annual report on global drug spending predicts a slight rebound in developed markets, despite historically low growth rates. In emerging markets, growth continues to be robust, but is it enough to balance the ongoing stagnancy in Europe and the US?
Posted in Emerging Markets, Europe, Global, Market Access, Strategy, leadership, pricing | Also tagged , , , , | Leave a comment

Tasty Asian Acquisition for Publicis

By Guest Blogger | Published: February 23, 2012
Publicis Healthcare Gobbles Up Another Asian Agency Publicis continues its expansion into Asia with today’s (Feb 20) announcement of its acquisition of U-Link Business Solutions (UBS), one of China’s leading agencies specializing in healthcare communications. As a part of Publicis Healthcare Communications Group, the agency will be renamed UBS Saatchi & Saatchi Health. “The Chinese healthcare market is [...]
Posted in Agency Insight, Emerging Markets, Global, Guest Blog | Also tagged , , , | Leave a comment

FDA Finding Fuels Indian Crackdown on Sub-standard Drugs

By Guest Blogger | Published: July 27, 2011
By Mangesh Sai, Asia Correspondent. A routine monthly inspection carried out by the Food and Drugs Administration (FDA) authorities in the state of Maharashtra, India, last month noted an increase in the number of sub-standard drug samples raising apprehensions about the availability of safe and genuine drugs in the state. Officials pointed out that 26 drug samples [...]
Posted in Anti-counterfeiting, Global, Guest Blog, IP, Safety | Also tagged , , , | Leave a comment

Planning Beyond the Petri Dish: A Pfizer Case Study

By William Looney | Published: June 29, 2011
Pfizer’s crizotinib development program combined organization, art, and science— and a large dose of unforeseen risk. The path to commercializing a breakthrough discovery is rarely a linear process. The orderly rationale of the scientific method is often overtaken by the random artistry of passion, personality, business culture, and sheer luck. Each plays a [...]
Posted in Emerging Markets, Global, R&D | Also tagged , , , , , , | Leave a comment